Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30340042.
- Also identified by DOI 10.1016/j.cell.2018.09.027 and PMC identifier 6422358.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The super elongation complex (SEC) is required for robust and productive transcription through release of RNA polymerase II (Pol II) with its P-TEFb module and promoting transcriptional processivity with its ELL2 subunit. Malfunction of SEC contributes to multiple human diseases including cancer. Here, we identify peptidomimetic lead compounds, KL-1 and its structural homolog KL-2, which disrupt the interaction between the SEC scaffolding protein AFF4 and P-TEFb, resulting in impaired release of Pol II from promoter-proximal pause sites and a reduced average rate of processive transcription elongation. SEC is required for induction of heat-shock genes and treating cells with KL-1 and KL-2 attenuates the heat-shock response from Drosophila to human. SEC inhibition downregulates MYC and MYC-dependent transcriptional programs in mammalian cells and delays tumor progression in a mouse xenograft model of MYC-driven cancer, indicating that small-molecule disruptors of SEC could be used for targeted therapy of MYC-induced cancer.
Medical subject headings
- Antineoplastic Agents
- Neoplasms, Experimental
- Positive Transcriptional Elongation Factor B
- Repressor Proteins
- Transcription Elongation, Genetic
- Transcriptional Elongation Factors